Cheap supplies of HIV-prevention jab for poorer countries hailed as ‘genuine chance to end’ global epidemic | Aids and HIV
The cheap supplies of a revolutionary HIV prevention jab will be revolutionary will be available in many poor countries within two years, have promised donors.
Lenacapavir will cost $ 40 (£ 30) one patient per year in 120 low and intermediate income countries from 2027, under two agreements of generic drugs announced this week.
Last year, there were 1.3 million new HIV infections worldwide and that experts said that Lenacapavir, as a preventive drug or “pre-exhibition prophylaxis” (PREP), could have a transformative effect on this figure. The drug, given as injection every six months, has almost completely prevented new HIV cases in clinical trials.
The World Health Organization recommended this as a preventive medication in July, with the director general, Dr. Tedros Adhanom Ghebreyesus, describing him as “the following best” to a HIV vaccine.
There had been questions about the question of whether the drug would be affordable enough to make a difference in countries with the highest rates of HIV. He was launched in the United States with a list price of $ 28,218 per year.
Gilead, who has created the drug on the market, has now granted voluntary licenses to six generic manufacturers, including Dr. Reddy’s and Hetero Labs, to provide the product in 120 low and intermediate income countries through HIV national programs and organizations such as the Global Fund.
Unitaid, the Clinton Health Accessive Initiative (CHAI) and the RHI WITS based in Johannesburg have concluded a partnership with Dr. Reddy’s Laboratories, while the Gates Foundation has an agreement with Hetero Labs.
The price of $ 40 will put the injectable drug in the same support as HIV prevention pills, that many people at risk of infection have trouble taking. Stigmatization surrounding HIV often means that they want or need to hide the fact that they take them.
The director of Unitaid, Dr. Philippe Duneton, said: “Securing a price of $ 40 for the injection of Lénacapavir twice paragraph for preparation is a historic breakthrough which proves that the most advanced tools can be made affordable from the start.”
Chronology
Eight key dates in the fight against AIDS and HIV
To show
.
The first reports of a mysterious and fatal disease affecting homosexuals in the United States appear in scientific journals.
Scientists from the Pasteur Institute in Paris report the discovery of a virus that could be the cause of AIDS – now known as HIV.
The first antiretroviral drug (ARV) to combat HIV and AIDS is approved by the American Food and Drug Administration. The 1990s will see enormous advances in the treatment that saw deaths fall for those who can afford medication.
Generic pharmaceutical companies propose to produce cheaper forms of ARV for developing countries. There are more than 20 million people living with HIV in Africa, but practically no access to drugs.
The President’s emergency plan for the relief of AIDS (PEPFAR) is announced by George W Bush to tackle HIV and AIDS in the countries harshly affected in the world. He will ultimately invest more than $ 110 billion (84 billion pounds sterling) and will prevent millions of infections and deaths.
The first remedy: doctors announce that Timothy Ray Brown of San Francisco is free from HIV after having undergone a bone marrow transplant to treat leukemia.
The UN sets a Sustainable Development Goal (SDG) to end aid as a public health threat by 2030.
Antiretroviral drugs to treat HIV were not available in sub -Saharan Africa for about a decade after they became an option for people living with HIV in high -income countries.
Bill Clinton, the former American president who co -founded Chai, said that the deployment of Lenacapavir represented “a real chance to end the world HIV epidemic.
Beatriz Grinsztejn, president of the International Aids Society, said: “We congratulate ourselves that are affordable Lenacapavir – a vital step to extend access – but availability in 2027 still feels far.”
“With HIV’s response in a funding crisis, countries are already making difficult compromises,” she said. “To achieve the full potential of this innovation, preparation options like Lenacapavir must reach the most vulnerable people, which requires an urgent and additional investment to avoid delays or refuse access.”
There has been efforts to increase access to the period when generics do not become available, with Pepfar, Global Fund and Children’s Investment Fund Foundation promising funding to obtain preventive lenacapavir for low and average income countries (LMIC). Gilead said he would provide them with the drug without profit.
However, the Trump administration suggested that its funding should only apply to Lenacapavir for pregnant and breastfeeding women, which would exclude other high -risk groups such as men who have sex with men, sex workers, people who consume drugs and prisoners.
In addition, many countries with an increasing number of HIV cases do not appear on the list of 120 “countries with income with a high delivery of resources” which were contained with Gilead.
Unitaid said that it “remains determined to process access obstacles in countries not covered by existing agreements”.
